| 36368129 | Profiling the immune landscape in mucinous ovarian carcinoma. | Gynecol Oncol | 2023 |
| 37845213 | Molecular landscape and functional characterization of centrosome amplification in ovarian cancer. | Nat Commun | 2023 |
| 37875466 | Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. | Nat Commun | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 36539619 | Author Correction: Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro. | Nat Genet | 2023 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 36860310 | Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study. | Front Oncol | 2023 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 35785153 | Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. | Front Oncol | 2022 |
| 36105417 | Magnetization transfer imaging of ovarian cancer: initial experiences of correlation with tissue cellularity and changes following neoadjuvant chemotherapy. | BJR Open | 2022 |
| 36289203 | Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. | Nat Commun | 2022 |
| 36222710 | Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. | Clin Cancer Res | 2022 |
| 33720084 | Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. | Int J Gynecol Pathol | 2022 |
| 33315123 | Ultrasound-guided targeted biopsies of CT-based radiomic tumour habitats: technical development and initial experience in metastatic ovarian cancer. | Eur Radiol | 2021 |
| 33901270 | Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance. | J Clin Endocrinol Metab | 2021 |
| 33725187 | Non-contrast MRI can accurately characterize adnexal masses: a retrospective study. | Eur Radiol | 2021 |
| 34857954 | Mapping the temporal and spatial dynamics of the human endometrium in vivo and in vitro. | Nat Genet | 2021 |
| 34289327 | MRI findings in-between leiomyoma and leiomyosarcoma: a Rad-Path correlation of degenerated leiomyomas and variants. | Br J Radiol | 2021 |
| 34233457 | MRI of the endometrium - from normal appearances to rare pathology. | Br J Radiol | 2021 |
| 34111973 | Diagnostic interpretation of non-contrast qualitative MR imaging features for characterisation of uterine leiomyosarcoma. | Br J Radiol | 2021 |
| 32350471 | The mutational landscape of normal human endometrial epithelium. | Nature | 2020 |
| 35122049 | Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis. | Nat Cancer | 2020 |
| 32075097 | <i>PIK3R1</i><sup>W624R</sup> Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. | Cells | 2020 |
| 31829441 | p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. | J Pathol | 2020 |
| 32555365 | Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. | Br J Cancer | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 31032385 | Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. | Eur J Radiol Open | 2019 |
| 31239549 | A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. | Mod Pathol | 2019 |
| 31341212 | Diffusion kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. | Sci Rep | 2019 |
| 29502561 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. | Mayo Clin Proc | 2018 |
| 30104763 | Copy number signatures and mutational processes in ovarian carcinoma. | Nat Genet | 2018 |
| 30062862 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2018 |
| 30404863 | Enhanced detection of circulating tumor DNA by fragment size analysis. | Sci Transl Med | 2018 |
| 28931370 | Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer. | BMC Cancer | 2017 |
| 28359078 | Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. | Br J Cancer | 2017 |
| 29049607 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | JAMA Oncol | 2017 |
| 28881617 | Germline whole exome sequencing and large-scale replication identifies <i>FANCM</i> as a likely high grade serous ovarian cancer susceptibility gene. | Oncotarget | 2017 |
| 26681675 | Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. | Ann Oncol | 2016 |
| 27997533 | Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. | PLoS Med | 2016 |
| 27208206 | New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. | J Med Genet | 2016 |
| 27552403 | Prevalence of Appendiceal Lesions in Appendicectomies Performed During Surgery for Mucinous Ovarian Tumors: A Retrospective Study. | Int J Gynecol Cancer | 2016 |
| 25710373 | Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. | PLoS Med | 2015 |
| 26315354 | Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. | J Natl Cancer Inst | 2015 |
| 26261251 | Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. | J Clin Oncol | 2015 |
| 25962114 | Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. | Int J Gynecol Cancer | 2015 |
| 24728189 | The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. | Hum Mol Genet | 2014 |
| 25608477 | Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. | Genome Biol | 2014 |
| 25349970 | Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. | Br J Cancer | 2014 |
| 23845225 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. | Lancet Oncol | 2013 |